U.S. Patent & Trademark Office (USPTO) Issues Patent to Elorac, Inc. for Novel Acne Therapy

06-02-2014 Business Wire HealthComments (0)

DermatologicalsPharmaceuticalUSA

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the USPTO has issued U.S. Patent No. 8,604,047 entitled “Method and Composition for Treating Nodulocystic and Conglobate Acne Vulgaris.” This patent provides for once-weekly oral administration of selective inhibitors of type 1 and/or type 2 isoforms of steroid 5α-reductase to patients with nodulocystic and conglobate acne vul

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top